Albuminar Articles
Proposed new Therapeutic Goods Orders from Australia’s TGA
23 September 2009
InVitria's Cellastim improves cell growth
30 April 2009
Locteron shows better AE profile than PEG-Intron
24 April 2009
Japan stock market week to March 30, 2009
31 March 2009
Biovitrum signs deal for Affibody drugs
30 March 2009
Abraxane rights cost deepens Abraxis' loss
16 March 2009
Biopartners to appeal CHMP's Biferenox dismissal
2 March 2009
GSK doses first patient in Ph III Syncria trial
23 February 2009
Ajinomoto and Eisai in Livact deal for Asia
16 February 2009
Abraxane launched in Germany
9 February 2009
18% of BC patients see complete response with Abraxane regimen
22 December 2008
Abraxis launches Abraxane in EU
22 December 2008
Abraxane gains marketing OK in Australia
27 October 2008
Baxter sales up 15% in 3rd-qtr 2008
27 October 2008
Cytochroma initiates Ph II trial of CTA018
27 October 2008
Grifols breaks ground on new IVIG facility
13 October 2008
NCCN to test Abraxane for SPARC benefits
13 October 2008
Biocon/Abraxis debut Abraxane in India
28 July 2008
Abraxis to appeal ruling on Elan patent
23 June 2008
Japan stock market week to May 26, 2008
2 June 2008
Novozymes grants technology licences to Dyax
26 May 2008
Locteron achieves 100% EVR in SELECT-1 trial
5 May 2008
Abraxis reports Phase I results for Abraxane
28 April 2008
CSL Behring licenses Novozymes' albufuse
14 April 2008
Taiho submits Japanese NDA for Abraxis BioSci's Abraxane
24 March 2008
China breaks up fake human albumin gang
24 March 2008
Abraxis licenses Abraxane to Green Cross for Korea
3 December 2007
Akela sees positive Ph II results with its GHRA
19 November 2007
Teturna cuts level of proteinuria in diabetics
19 November 2007
Abraxane gets CHMP nod for breast cancer
29 October 2007
Baxter's 3rd-qtr 2007 net income rises 6%
29 October 2007
CRT, Novozymes and UCL to collaborate on MFE-23 research
17 September 2007
Biferonex MAA submitted to EMEA
3 September 2007
Novartis and HGS to collaborate on Albuferon R&D
12 June 2006
Abraxis to buy Puerto Rico unit from Pfizer
1 May 2006
APP and American Biosci complete merger to form Abraxis
24 April 2006
American Pharma to buy shareholder
5 December 2005
Stock Commentary - Tokyo week to Aug 15
5 September 2005
Japan stock market two week to August 29
5 September 2005
Abraxane Ph II trial finishes recruitment
16 May 2005
APP reports start of Ph II trial of Abraxane/Herceptin
18 April 2005
Baxter's Advate shows good market acceptance
14 March 2005
Strong results for APP's Abraxane
7 March 2005
Abraxane cleared for breast cancer by FDA
17 January 2005
GSK licenses Human Genome Sci's Albugon
1 November 2004
Bayer Biologicals moves to stop counterfeiting
26 July 2004
Baxter gets FDA warning on ADVATE promotion
7 June 2004
Abraxane filed for US approval
15 March 2004
Serologicals expands distribution deal with Novo Nordisk
15 March 2004
CSL's first half of 2004 net profit dives 37%
23 February 2004
GTC Bio restructures to support programs
9 February 2004
Novo Nordisk
8 September 2003
FDA approves Baxter hemophilia drug
4 August 2003
Spain: Probitas serum plant completed
28 July 2003
Tokyo pharma stocks - week to July 14
21 July 2003
Tokyo pharma stocks - week to June 16
23 June 2003
Spain's Probitas seeking stock listing
2 June 2003
BioPartners, Rentschler to take on MS market
20 January 2003
Baxter files in USA for albumin-free rFVIII
8 July 2002
Merck & Co is utilizing Recombumin with Delta's vaccine
7 January 2002
Merck & Co is utilizing Recombumin with Delta's vaccine
19 December 2001
China: drug price cuts lead to competition
2 August 2001
Fresenius obtains rights from Genzyme
19 July 2001
Japan pharma stocks - week to July 9
11 July 2001
HGS Albutropin IND cleared by FDA
6 June 2001
HGS starts trials of Albuferon in HCV
26 March 2001
Stock Commentary - Tokyo
22 February 2001
Human Genome Sciences buying Principia Pharma Corp for $120 million
11 September 2000
Bayer gets FDA OK for Cipro anthrax use
4 September 2000
Bayer gets FDA OK for new Kogenate
3 July 2000
Stock Commentary Tokyo
8 June 2000
Stock Commentary Tokyo
25 May 2000
Pharma sales push Aventis' turnover up
3 May 2000
Bayer wins positive opinion for Kogenate
28 March 2000
China sees over-supply, low demand for drugs
16 March 2000
AHP launch for Refacto in UK
22 June 1999
EU approves AHP's ReFacto
16 April 1999
Stock Commentary Tokyo
14 April 1999
Enzon - improving the delivery and side effect profile of proven
20 January 1999
ReFacto Labeling Endorsed
14 December 1998
AviGenics To Produce Drugs In Genetically-Engineered Chickens
9 December 1998
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
